News | Cath Lab | November 09, 2016

Coronary Stent Study Evaluates Adverse Events in Women, Minorities

Results from the PLATINUM DIVERSITY Study presented at TCT 2016 

 PLATINUM DIVERSITY, stents in minorities and women

November 9, 2016 — A dedicated stent study conducted exclusively in women and minority patients evaluated clinical outcomes within the era of contemporary percutaneous coronary interventions (PCI), comparing these results to a parallel cohort of white male patients. Although there were no significant differences in stent-related outcomes, both groups had higher rates of death and myocardial infarction (MI) in the first year following the procedure. 

Findings from the PLATINUM DIVERSITY trial were reported at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. 

Although people of color are expected to represent more than half (52%) of the U.S. population by 2050, current “all-comers” clinical trial design do not result in a random selection of U.S. patients. As a result, women and minorities have been significantly underrepresented in most cardiology trials. This multicenter, single-arm, prospective “enriched” cohort study enrolled 1,501 women and minorities at 52 sites in the United States. The trial used the Boston Scientific Promus Premier everolimus-eluting stent. Patient information was pooled with data from the PROMUS ELEMENT PAS Study (PE Plus PAS, n=2,687) and each group was compared with white men enrolled in the PE Plus PAS (n=1,635).

“This study draws important attention to differences in clinical outcomes after stent implantation in women and minorities,” said Wayne B. Batchelor, MD, MHS, co-principal investigator from Southern Medical Group in Tallahassee, FL. “The adjusted risk of MI and death/MI was higher in minorities versus white men. In addition, the adjusted risk of death/MI was higher in women than white men with a trend towards higher rates of MI. The similar rates of TVR and stent thrombosis among all three groups suggest that ‘stent failure’ is unlikely to account for the observed differences in outcome. Further study into the cause of these observed gradients of risk is necessary to gain insight into the potential impact on clinical practice.”

The combined primary endpoint of death, Ml and target vessel revascularization (TVR) at 12 months was 7.6% for white men compared with 9.6% (P=0.08) for minorities and 8.6% (P=0.33) for women. Data from the individual components of the primary endpoint found that minorities had the highest rate of death and MI whereas white men had the highest rate of TVR:

•    Death was 3.7% in minorities (P=0.03) and 3.4% in women (P=0.04) compared with white men (2.2%).
•    MI was 3.1% (P=0.0002) in minorities and 1.9% in women (P=0.06) compared with white men (1.1%).
•    TVR was 5.4% (P=0.97) in minorities and 4.6% in women (P=0.27) compared with white men (5.5%).

“The PLATINUM DIVERSITY trial represents an important example of how we can enrich our understanding of outcomes in the underrepresented population. This is the first trial exclusively enrolling women and minorities undergoing PCI and allows for further evaluation of patients who are usually not represented in clinical studies,” said Roxana Mehran, M.D., professor of medicine, Icahn School of Medicine at Mount Sinai and Co-PI of the PLATINUM DIVERSITY study.

The PLATINUM DIVERSITY trial was funded by Boston Scientific. Batchelor reported grant/research support from Boston Scientific and consulting fees/honoraria from Abbott, Boston Scientific and Medtronic.

Read the article “Boston Scientific Initiates Study Of Promus Premier Coronary Stent in Underserved Patient Populations."

 
For more information: www.crf.org

Related Content

Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019
A program designed to help heart attack patients with the transition from hospital to outpatient care can reduce...
TherOx Receives FDA Approval for SuperSaturated Oxygen Therapy
Technology | Cath Lab | April 08, 2019
TherOx Inc. announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its...
Cook Medical Recalls Transseptal Needle Due to Risk of Detached Plastic Fragments
News | Cath Lab | March 20, 2019
March 20, 2019 — Cook Medical is recalling one lot of its...
Overlay Init